New Diabetes Treatments-Enhanced blood flow

Three diabetes treatments with entirely new modes of action were approved: exenatide injection for people with type 2 diabetes, pramlintide injection as an add-on to insulin therapy for people with type 1 or type 2 diabetes and Sitagliptin also for people with type 2 diabetes. Some diabetes medications help the pancreas release more insulin (if you have type 2 diabetes), others help cells use insulin better, and others keep the liver from releasing too much glucose. The new treatments focus action on hormones called incretins.
Exenatide injection:

  • is injected twice a day at mealtime
  • is for those with type 2 diabetes who have been unable to control blood glucose with oral medicines
  • improves blood glucose control by mimicking incretin hormones, stimulating insulin and slowing stomach-emptying
  • leads to weight loss because patients will feel full faster and stop eating
  • can cause nausea

Exenatide extended release  is  injected once per week is for those with type 2 diabetes who have been unable to control blood glucose with oral medicines  that helps to improves blood glucose control by mimicking incretin hormones, stimulating insulin and slowing stomach-emptying leads to weight loss because patients will feel full faster and stop eating which can cause nausea.

Pramlintide acetate is intended for those with type 1 or type 2 diabetes who use insulin

  • is injected at mealtime
  • is to never mix with insulin in one syringe; which creates the need for an additional injection for the patient
  • used for better glucose control, reduction in blood glucose spikes, reduction in food intake, whichleads to weight loss
  • can cause nausea or hypoglycemia (dangerously low blood glucose)

Sitagliptin Saxagliptin and linagliptin-All three of these pills

  • are taken once a day
  • are for type 2 diabetes
  • do not promote weight gain
  • are often used in combination with metformin
  • have very little, if any, side effects
  • Should be taken with caution for patients with renal disease (dose should be decreased)
  • slows the breakdown of incretins, so insulin is released over a longer period of time

  • Liraglutide Injection
  • Exenatide Injection
  • Exenatide extended release Injection
  • Pramlintide acetate(Mealtime Injection)
  • Sitagliptin and Metformin (Dipeptidyl Peptidase-4 Inhibitors)
  • Saxagliptin and Metformin
  • Linagliptin and Metformin

Related Conference of New Diabetes Treatments-Enhanced blood flow

November 28-29, 2022

International Conference on Diabetes & Heart Diseases

Yokohama, Japan
November 28-29, 2022

14th World Congress on Endocrinology and Metabolic Disorders

Amsterdam, Netherlands
January 30-31, 2023

6th Annual Meeting on Diabetes and Endocrinology

Barcelona, Spain
February 22-23, 2023

32nd European Diabetes Congress

Madrid, Spain
March 27-28, 2023

56th Annual Congress on Endocrinology & Disorders

Vancouver, Canada
April 18-19, 2023

Global Summit on Endocrinology

Madrid, Spain
April 18-19, 2023

European Endocrinology and Diabetes Congress

Madrid, Spain
May 15-16, 2023

4th Global summit on Diabetes and Endocrinology

Madrid, Spain
June 05-06, 2023

World Congress on Endocrine and Diabetes

San Francisco, USA
June 15-16, 2023

4th Annual conference on Diabetes

San Francisco, USA
July 24-25, 2023

19th International Conference on Diabetes & Care

Venice, Italy
August 10-11, 2023

25th World Congress on Diabetes and Endocrine Disorders

Dublin, Ireland
September 12-13, 2023

7th Annual Conference on Diabetes and Endocrinology

Barcelona, Spain
October 21-22, 2023

4th World Summit on Diabetes Expo

New York, USA

New Diabetes Treatments-Enhanced blood flow Conference Speakers

Recommended Sessions

Related Journals

Are you interested in